Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF ...

HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s ...

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...